Lorena Hernandez-Bellido - Publications

ctDNA-derived copy-number signatures associated with immune checkpoint inhibitor resistance beyond PD-L1 and TMB in advanced NSCLC.

Journal: Frontiers in oncology

Published: May 08, 2026

Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.

Journal: Scientific reports

Published: January 17, 2026

Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report.

Journal: Translational lung cancer research

Published: January 09, 2026

Case Report: Mucoepidermoid carcinoma of the lung, a challenging diagnosis of an unusual case.

Journal: Frontiers in oncology

Published: May 11, 2025

A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 14, 2025

Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.

Journal: Translational lung cancer research

Published: January 17, 2025

Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?

Journal: Current oncology (Toronto, Ont.)

Published: September 11, 2024

Active treatment at the end of life-importance of palliative care in advanced non-small cell lung cancer: a cohort study.

Journal: Annals of palliative medicine

Published: June 22, 2024

Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50.

Journal: Translational lung cancer research

Published: June 16, 2024

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 08, 2023

Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 30, 2023

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data.

Journal: Cancers

Published: July 02, 2023